Table 4.
Initial antibiotics treatment and clinical outcomes by severity of community-acquired pneumonia (CAP)
| All Patients (n = 94) |
Severe CAP (n = 50) |
Non-severe CAP (n = 44) |
p-value | |
|---|---|---|---|---|
| Etiological diagnosis | 43 (45.7) | 28 (56) | 15 (34.1) | .03* |
| Positive blood culture | 14 (14.9) | 12 (24) | 2 (4.5) | .008* |
| Potentially drug-resistance bacteria | 21 (22.3) | 13 (46.4) | 8 (53.3) | .36 |
| Combination therapy | 57 (60.6) | 30 (60) | 27 (61.4) | .89 |
| Guideline-concordant antibiotic therapya | 54 (57.4) | 24 (48) | 30 (68.2) | .048* |
| Guideline- discordant antibiotic therapy:a | 40 (42.6) | 26 (52) | 14 (31.8) | |
| β-lactams without quinolone or macrolide: | 33 (35.1) | 20 (40) | 13 (29.5) | |
| Nonantipseudomonas β-lactams without quinolone or macrolide | 9 (9.6) | 4 (8) | 5 (11.4) | |
| Antipseudomonas β-lactams without quinolone or macrolide | 24 (25.5) | 16 (32) | 8 (18.2) | |
| Quinolone without β-lactams | 5 (5.3) | 5 (10) | 0 | |
| Macrolide without β-lactams | 2 (2.1) | 1 (2) | 1 (2.3) | |
| Inadequate initial antibiotic treatmentb | 11/43 (25.6) | 9/28 (32.1) | 2/15 (13.3) | .28 |
| Initial antibiotic regimen was modified | 37 (39.4) | 26 (52) | 11 (25) | .008* |
| Treatment failure | 27 (28.7) | 23 (46) | 4 (9.1) | <.001* |
| Death | 18 (19.1) | 14 (28) | 4 (9.1) | .02* |
| Unfavorable outcomec | 31 (32.9) | 25 (50) | 6 (13.6) | <.001* |
| Hospital-free day, dd | 15.4 ± 9.8 | 11.6 ± 9.9 | 19.7 ± 7.7 | <.001* |
Data are presented as mean ± SD or n (%), unless otherwise stated. aThe 2007 ATS/IDSA guidelines on the management of community-acquired pneumonia in adults. bPathogens detected were not susceptible to the antibiotics administered within 24 h of presentation. cUnfavorable outcome includes treatment failure or death during hospital admission. dNumber of days from admission to day 30 that the patient was not admitted to the hospital. *Statistically significant difference